linjc16/ctgov huggingface dataset:
Lazertinib 160mg in EGFR T790M NSCLC

Study Overview
=================
Brief Summary
-----------------
The lazertinib is currently approved as 2nd line T790M mutation-positive NSCLC that failed from either 1st or 2nd generation EGFR TKI. The current recommended dosage is 240mg. Based on the promising clinical efficacy of the dose escalation study, this study is designed to evaluatee the clinical efficacy and safety of 160mg lazertinib.

Official Title
-----------------
A Phase II Study for the Evaluation of the Feasibility of Lazertinib 160mg Per Day in Patients With EGFR T790M Mutant Non-small Cell Lung Cancer

Conditions
-----------------
Lung Cancer Stage IV, EGFR T790M

Intervention / Treatment
-----------------
* Drug: Lazertinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically confirmed non-small cell lung cancer Patients in a palliative setting who is not applicable for the curative treatment EGFR mutation positive patients who received previous 1st or 2nd generation EGFR TKI Confirmed EGFR T790M mutation after the previous EGFR TKI Available to receive lazertinib either as po or vis levine tube Willing to participate clinical trial Age over or equal to 19 ECOG PS 0 to 2 Exclusion Criteria: Previously received 3rd generation EGFR TKI No clinical benefit is expected based on the investigator's decision Uncontrolled symptomatic CNS metastases Uncontrolled systemic disease

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lazertinib 160mg arm<br> | Drug: Lazertinib<br>* 160mg po qd<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The dose reduction or treatment discontinuation rate | Dose who received dosage below 160mg or discontinued due to the adverse event | Total 24 months of study period |
Effects of Low LH Serum Levels on Ovarian Pick-up Outcome

Study Overview
=================
Brief Summary
-----------------
Luteinizing hormone (LH) plays a key role for normal follicular development and oocyte maturation in controlled ovarian stimulation. In particular, LH stimulates the proliferation and differentiation of theca cells for the secretion of androgens, which synergistically increase the production of estrogen. This study aimed to investigate the effects of low LH concentrations on oocyte retrieval, fertilization and embryo development in patients undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). Patients undergoing IVF/ICSI were prospectively analyzed, subdividing them into three groups according to their age. Serum LH levels were evaluated at day 3, during stimulation (day 10) and before ovulation induction (day 12).

Official Title
-----------------
Effects of Low LH Serum Levels on Oocyte Retrieval, Fertilization Rate and Embryo Quality During Controlled Ovarian Stimulation: Results From a Prospective Cohort Analysis

Conditions
-----------------
Infertility, Female, ART

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18 and 40 years, body mass index 18-29 kg/m 2 , regular menstrual cycles, normal uterine cavity assess by hysteroscopy, normal uterus and ovaries at transvaginal sonography, Exclusion Criteria: abnormal cervical cytology, affected by any other endocrinological, metabolic, autoimmune, and gynecological disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oocyte retrieval | number of retrieved oocytes after controlled ovarian stimulation | immediately after the intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
embryo quality, LH levels, Oocyte retrieval
OCT Eccentric Fixation and Amblyopia in Children

Study Overview
=================
Brief Summary
-----------------
The objectives of this proposal are to characterize the relationship between OCT eccentric fixation (OCT-EF), fixation eye movement (FEM), macular sensitivity in children with amblyopia.

Detailed Description
-----------------
Aim 1. OCT EF changes with patching treatment at 12 weeks visit. Aim 2. OCT EF changes with foveation therapy.

Official Title
-----------------
OCT Eccentric Fixation, Fixation Stability, and Amblyopia in Children

Conditions
-----------------
Amblyopia

Intervention / Treatment
-----------------
* Device: eye patch
* Device: After-image and MIT trainer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children with best-corrected visual acuity (BCVA) of 20/40 (equivalent to 0.3 logMAR) or worse in the amblyopic eye (ranging from 20/40 to 20/400), and interocular difference of BCVA was at least two logMAR lines, ocular causes of amblyopia that were identified as refractive(i.e., anisometropic, strabismus, or strabismic-anisometropic. Anisometropia included interocular difference of spherical equivalent >=1D or interocular difference of astigmatism cylinder magnitude >=1D; strabismus included those with deviation >=10PD or good alignment after prior strabismus surgery; combined type included those who meet the criteria of both anisometropia and strabismus. For the patching group, we will enroll 15 children with strabismic amblyopia who are prescribed patching treatment. Age: 4-12 years old. For the foveation therapy group, we will enroll 15 children with strabismic amblyopia who are prescribed foveation therapies. Age: 8-16 years old. Exclusion Criteria: born before 32 weeks gestational age; neurologic, developmental, or systemic illnesses known to be associated with ocular pathologies; congenital or acquired macular pathology.

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patching group<br>part-time patching following PEDIG guidelines. | Device: eye patch<br>* standard amblyopia treatment<br>|
| Experimental: foveation therapy<br>After-image foveation therapy training is 10 mins; MIT training is 5 minutes. | Device: After-image and MIT trainer<br>* Common clinical training for foveation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OCT eccentric fixation | eccentric fixation measured with OCT imaging. | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
eccentric fixation, amblyopia, patching, foveation therapy, OCT
Mealtime Anxiety in Eating Disorders

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to assess mealtime anxiety in patients with eating disorders receiving treatment at an in-patient unit. Anxiety wil be assessed using ecological momentary assessment (EMA). The main research question is: • Does post meal activity reduce anxiety in patients with eating disorders? Study participation will last for two weeks. Participants will be reporting current levels of anxiety/distress on an EMA mobile app during treatment as usual. During one of the two study participation weeks, the participants will perform post mealtime activity.

Official Title
-----------------
Mealtime Anxiety in Eating Disorders: An Ecological Momentary Assessment (EMA) Project

Conditions
-----------------
Eating Disorders

Intervention / Treatment
-----------------
* Behavioral: Post mealtime activity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted to the Regional Department for Eating Disorders adult in-patient unit (>16 years old) will be invited to participate. Exclusion Criteria: Patients who receive tube feeding for all meals during the study period will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with eating disorders<br> | Behavioral: Post mealtime activity<br>* Therapist lead movement post meals<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Self Reported Anxiety During Treatment as Usual vs Treatment as Usual plus Post-Mealtime Activity | Anxiety will be measured using the Subjective Units of Distress Scale (SUDS). Higher scores indicate higher levels of distress. The Affect Grid will also be used to assess current mood. Measures will be collected using Ecological Momentary Assessment (EMA). | Two weeks |
HERA AFIb Registry for Patients With Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
The single-center HERA AFIb registry was created to assess real-world prevalence, demographic characteristics and management of patients with atrial fibrillation (AF) in the era of novel oral anticoagulant regimes (NOAC) presenting in the emergency department (ED) of University of Heidelberg

Detailed Description
-----------------
HERA AFIb is a single-center retrospective registry which enrolled consecutive cases presenting with atrial fibrillation at the emergency department of University Hospital of Heidelberg. Clinical parameters and characteristics for cases were assessed retrospectively. Follow-up was performed via review of medical reports, phone calls and postal queries. Outcome parameters included rates for all-cause mortality, non-hemorrhagic stroke, myocardial infarction and major bleeding.

Official Title
-----------------
HERA AFIb Registry

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Other: no intervention is planned.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: documented atrial fibrillation availability of at least one hsTnT measurement Exclusion Criteria: lost to follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| atrial fibrillation<br>cases presenting with atrial fibrillation at the emegency department. | Other: no intervention is planned.<br>* no intervention is planned.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality | all-cause mortality during follow-up | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ischaemic stroke | ischaemic stroke during follow-up | 24 months | 
| major bleeding | major bleeding during follow-up | 24 months | 
| myocardial infarction | myocardial infarction during follow-up | 24 months |
A Multicenter Study of Retrospective Rehabilitation Medical Data for the Development for Medical Twins

Study Overview
=================
Brief Summary
-----------------
Based on previous studies, when medical digital twin-based convergence medical contents are applied to degenerative musculoskeletal and central nervous system diseases, it is possible to more accurately evaluate the subject's motor function and neurological function to predict the subject's disease. In order to create an effective ICT application protocol and clinically apply a treatment program that can improve the subject's kinematic function and neurological function, etc.

Official Title
-----------------
A Multicenter Study of Retrospective Rehabilitation Medical Data for the Development for Medical Twins

Conditions
-----------------
Health-Related Behavior, Stroke

Intervention / Treatment
-----------------
* Diagnostic Test: Medical record collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy subjects : who underwent imaging examination at Bundang CHA hospital from January 1, 2010 to December 31, 2021 Stroke patients : who underwent imaging examination at Bundang CHA hospital from January 1, 2010 to December 31, 2021 Exclusion criteria - Who cannot meet the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy subjects and stroke patients<br>Healthy subjects and stroke patients | Diagnostic Test: Medical record collection<br>* Medical record collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Imaging examination | The results of X-ray measurement in whole spin AP and lateral, low extremty AP & lateral, foot AP & lateral, The results of multispine computed tomography of C-spine, T-spin and L-spine without CM, The results of magnetic resonance imaging of brain MRI and diffusion tensor imaging tractography | A time point at which imaging was performed between January 1, 2010 and December 31, 2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Basic characteristics | Sex, age, stroke onset, stroke diagnosis, history | A time point at which imaging was performed between January 1, 2010 and December 31, 2021 |
Transobturator Repair by Vaginal Plastron

Study Overview
=================
Brief Summary
-----------------
The autologous vaginal route consists of repairing the genital prolapse through the vagina using the patient's tissues without a prosthesis. Vaginal prostheses are actually currently prohibited in France [1, 2]. The autologous vaginal route is the quickest surgery and it can be done under spinal anesthesia, which constitutes arguments for offering it to elderly and fragile patients. The autologous vaginal approach gives functional and subjective results similar to promontofixation [2]. There are many surgical techniques that make it difficult to assess the recurrence rate in the literature. Autologous vaginal surgery provides a good degree of satisfaction for patients despite the risk of recurrence [3]. We propose to describe the results of the transobturator cystocele repair by vaginal plastron, a technique which seems reproducible and effective to us.

Official Title
-----------------
Transobturator Cystocele Repair by Vaginal Plastron

Conditions
-----------------
Anterior Prolapse Surgery Using the Transobturator Repair by Vaginal Plastron

Intervention / Treatment
-----------------
* Procedure: correction of anterior prolapse


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women over 18 patient who underwent surgery using the transobturator repair by vaginal plastron for correction of anterior prolapse requiring surgical correction of stage equal to or greater than II in the POP-Q classification intervention between September 2020 and October 2022 person having expressed his non-opposition Exclusion Criteria: inability to understand the information given person deprived of liberty person under guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| transobturator cystocele repair by vaginal plastron<br>patients who underwent surgery using the transobturator repair by vaginal plastron for correction of anterior prolapse | Procedure: correction of anterior prolapse<br>* percentage of failed prolapse correction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| failed prolapse correction | percentage of failed prolapse correction | at 1 month after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anterior prolapse, transobturator repair, vaginal plastron
Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor

Study Overview
=================
Brief Summary
-----------------
To investigate the treatment pattern and efficacy of patients with positive primary ER lesion but negative ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).

Official Title
-----------------
Negative Estrogen Receptor (ER) Expression Assessed by 18F-fluoroestradiol Positron Emission Tomography/Computed Tomography (18F-FES PET/CT) in the Metastatic Breast Cancer (MBC) With ER-positive Primary Tumor

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage. MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2010 and 2022 Patients diagnosed with primary ER-positive tumor and who were yet to receive any systemic therapy during the advanced stage Exclusion Criteria: Patients with incomplete medical records and those diagnosed with secondary primary tumors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| FES negative in MBC<br>Patients who did not present with any ER-positive lesions were characterized as with negative ER expression in the metastatic stage | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival (PFS) |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events | Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0 | 6 weeks |
Surgical Treatment of Hydatid Liver Disease

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to show that cyst extraction with pericyst reduction and omentopexy is a suitable treatment for liver hydatid disease caused by E.Granulossus with a low rate of complication and recurrence.

Official Title
-----------------
Cyst Extraction With Pericyst Reduction and Omentopexy as a Treatment of Choice for Hydatid Liver Disease Caused by E. Granulosus: Retrospective Observational Review of a Single Center Experience

Conditions
-----------------
Hydatid Cyst, Hepatic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hydatid liver disease Exclusion Criteria: hydatid disease present outside the liver

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post operative complications | Listing of complications according to Clavien -Dindo classification | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence rate | Recurrence rate of hydatid disease in patients | 5 years |
Exploring Clinical Study Experiences of People With Post Traumatic Stress Disorder

Study Overview
=================
Brief Summary
-----------------
Participation in post traumatic stress disorder observational study serves as a crucial contribution to advancing medical knowledge and refining the care provided to individuals facing similar health challenges. The primary objective centers on a meticulous examination of trial completion rates and voluntary withdrawals within this distinct patient population.

Official Title
-----------------
Examination of Participation Trends and Engagement Patterns of Participants in Post Traumatic Stress Disorder Clinical Trials

Conditions
-----------------
Post Traumatic Stress Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of post traumatic stress disorder No prior treatment for post traumatic stress disorder Willing and able to provide informed consent. Exclusion Criteria: Enrolled in another research study Psychiatric or behavioral illness Inability to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a post traumatic stress disorder clinical research. |  | 3 months | 
| Number of post traumatic stress disorder study participants who remain in clinical study until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Post Traumatic Stress Disorder